Go to the list of all blogs
published in Blogs
Aug 06, 2026
Warner Bros. Discovery (WBD) Trading 15% Below Paramount Skydance Deal Price Amid Antitrust Scrutiny

Warner Bros. Discovery (WBD) Trading 15% Below Paramount Skydance Deal Price Amid Antitrust Scrutiny

Key Takeaways

  • Warner Bros. Discovery shares hover near $26.30 as the proposed $110 billion acquisition by Paramount Skydance at $31 per share faces intensifying antitrust scrutiny from a 12-state coalition led by California.
  • A federal judge issued a temporary restraining order on July 20, pausing the merger through August 3, with a critical hearing on whether to extend the injunction now underway.
  • The company reports Q2 2026 earnings on August 6, with analysts forecasting a loss of $0.13 per share on revenue of approximately $9.29 billion, down 5.3% year-over-year.
  • Analyst sentiment reflects a cautious Hold consensus with an average price target of $27.04, though recent downgrades from Seaport Research Partners and Zacks Research underscore near-term headwinds.
  • WBD trades roughly 15% below the $31-per-share merger consideration, a discount that captures the market's assessment of deal-completion risk.

Current Market Snapshot

Warner Bros. Discovery shares have remained in a relatively tight range over the past 30 days, declining less than 1% from approximately $26.48 in early July to around $26.30 at the end of the month. The stock sits below both its 50-day moving average of $26.57 and its 200-day moving average of $27.28, reflecting a gradual erosion of momentum as investors weigh competing narratives: the transformative upside of a completed Paramount Skydance acquisition versus the growing legal and regulatory obstacles threatening the deal. The communication services sector has broadly faced pressure from cord-cutting trends and streaming profitability debates, and WBD has not been immune. Trading volume spiked to roughly 44 million shares on July 20 — more than double the three-month average — coinciding with the federal judge's restraining order, indicating heightened sensitivity to merger-related headlines. With a market capitalization near $65.9 billion and a beta of 1.55, WBD continues to attract both event-driven traders and value-oriented institutional investors assessing the risk-reward profile of the pending transaction. I also checked comparable names in the sector using Tickeron’s AI Screener to see how WBD stacks up on key metrics.

WBD Business Overview and Competitive Position

Warner Bros. Discovery is a global media and entertainment conglomerate formed through the 2022 merger of WarnerMedia and Discovery, Inc. The company's portfolio spans film and television production through Warner Bros. Studios, premium subscription streaming via HBO and HBO Max, a vast array of linear cable networks including CNN, TNT, TBS, Discovery Channel, TLC, and Animal Planet, as well as a growing direct-to-consumer streaming business. The company owns some of the most recognizable intellectual property franchises in entertainment, including Harry Potter, Game of Thrones, the DC Universe, and Lord of the Rings. In 2025, WBD generated approximately $37.3 billion in revenue across its Studios, Networks, and Direct-to-Consumer segments. The streaming division has been a particular focus, with HBO Max surpassing 140 million global subscribers in Q1 2026, driven by international launches in the U.K., Germany, Italy, and Ireland. Management has guided toward more than 150 million subscribers by year-end 2026, supported by marquee content releases and bundling partnerships. The company carries a debt-to-equity ratio of 0.92 and continues to navigate the industry-wide transition from linear television to streaming-centric consumption models.

Recent Developments Driving WBD

The dominant narrative for WBD remains the pending acquisition by Paramount Skydance (PSKY), announced in February 2026 at $31 per share in cash, representing an $81 billion equity value and $110 billion enterprise value. While WBD shareholders voted to approve the transaction, the deal encountered a significant obstacle on July 13 when California, leading a coalition of 12 states including New York, Colorado, and Massachusetts, filed an antitrust lawsuit alleging the merger would unlawfully reduce competition in film and television markets. A federal judge in Oakland granted a temporary restraining order on July 20, halting the deal's closure through August 3, with a hearing on a potential longer-term injunction now in progress. Adding complexity, California Governor Gavin Newsom has reportedly urged state Attorney General Rob Bonta to pursue an out-of-court settlement, citing concerns over potential job losses across the entertainment industry.

Meanwhile, the company's Q1 2026 results, reported on May 6, showed revenue of $8.89 billion — roughly flat year-over-year and in line with estimates — but a substantial earnings miss, with adjusted EPS of -$1.17 versus the consensus estimate of -$0.10. The miss was driven by restructuring and transaction-related costs tied to the pending merger. On the analyst front, Seaport Research Partners downgraded WBD from Buy to Neutral on July 27, and Zacks Research moved from Hold to Strong Sell on the same date. Conversely, Huber Research upgraded WBD from Underweight to Overweight on June 1, and UBS raised its price target to $31 on May 7. Guggenheim reiterated a Neutral rating in early July, forecasting a potential 65% year-over-year decline in Studios EBITDA for Q2. Internationally, European Union regulators are reportedly poised to approve the deal with remedies, while the UK Competition and Markets Authority is conducting its own review with a decision expected by August 7. Paramount has also extended debt tender and exchange offer deadlines to August 14, signaling continued commitment to closing the transaction. From what I see, the volume reaction on the restraining order date highlights just how sensitive the market remains to these updates.

2026 Outlook and What Investors Should Watch

The immediate focal point for WBD investors is the antitrust hearing on August 3 that will determine whether the temporary restraining order on the Paramount Skydance merger is extended. A prolonged injunction could push the deal past the September 30 threshold, at which point Paramount would owe a quarterly ticking fee of $0.25 per share — approximately $650 million per quarter — adding financial pressure to both parties. Beyond the courtroom, the company's Q2 2026 earnings report on August 6 will be closely scrutinized for subscriber growth metrics at HBO Max, linear advertising trends, and updated guidance on merger-related costs. Analysts will also monitor box office performance across the summer film slate, international streaming uptake, and any spillover effects from broader sector dynamics involving competitors such as NFLX and DIS. The UK CMA's decision on August 7 adds another regulatory checkpoint. With the stock trading at a notable discount to the merger price, the resolution of antitrust proceedings — whether through settlement, court ruling, or political intervention — remains the single most consequential variable for WBD's near-term trajectory. I’m watching this closely as the hearing unfolds.

Exploring Tickeron AI Tools for Event-Driven Analysis

In my own research on merger situations like this one, I frequently turn to Tickeron’s AI Trading Bots to model different scenarios around regulatory outcomes and volume patterns. The platform’s transparent performance metrics help me evaluate algorithmic approaches that align with the risk profile of stocks trading at a discount to deal prices, offering a data-driven complement to traditional analysis without introducing emotional bias.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: WBD

WBD's RSI Indicator recovers from oversold territory

The RSI Oscillator for WBD moved out of oversold territory on July 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In of the 34 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 64 cases where WBD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on August 05, 2026. You may want to consider a long position or call options on WBD as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for WBD just turned positive on August 05, 2026. Looking at past instances where WBD's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where WBD advanced for three days, in of 273 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

WBD moved below its 50-day moving average on July 17, 2026 date and that indicates a change from an upward trend to a downward trend.

The 50-day moving average for WBD moved below the 200-day moving average on August 05, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WBD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. WBD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.998) is normal, around the industry mean (20.961). P/E Ratio (93.862) is within average values for comparable stocks, (103.027). WBD's Projected Growth (PEG Ratio) (216.923) is very high in comparison to the industry average of (14.008). WBD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (1.771) is also within normal values, averaging (2.984).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. WBD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 77, placing this stock worse than average.

Notable companies

The most notable companies in this group are Netflix Inc. (NASDAQ:NFLX), Walt Disney Company (The) (NYSE:DIS), Roku (NASDAQ:ROKU), Paramount Skydance Corporation (NASDAQ:PSKY), AMC Entertainment Holdings (NYSE:AMC), iQIYI (NASDAQ:IQ), HUYA (NYSE:HUYA).

Industry description

Movies/entertainment industry include companies that produce and distribute motion pictures, and companies that operate general entertainment facilities like amusement parks and bowling centers. Some companies in this industry also have professional sports franchises. Live Nation Entertainment, Inc., Liberty Media Corp. and Viacom Inc. are some of the biggest companies in this space.

Market Cap

The average market capitalization across the Movies/Entertainment Industry is 17.25B. The market cap for tickers in the group ranges from 134 to 308.96B. NFLX holds the highest valuation in this group at 308.96B. The lowest valued company is LRDG at 134.

High and low price notable news

The average weekly price growth across all stocks in the Movies/Entertainment Industry was -1%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 10%. MCS experienced the highest price growth at 23%, while KWM experienced the biggest fall at -98%.

Volume

The average weekly volume growth across all stocks in the Movies/Entertainment Industry was 3%. For the same stocks of the Industry, the average monthly volume growth was -22% and the average quarterly volume growth was -47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 52
Price Growth Rating: 56
SMR Rating: 84
Profit Risk Rating: 76
Seasonality Score: -16 (-100 ... +100)
View a ticker or compare two or three
WBD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of multi-media educational and entertainment programming services

Industry MoviesEntertainment

Profile
Details
Industry
Cable Or Satellite TV
Address
230 Park Avenue South
Phone
+1 212 548-5555
Employees
35300
Web
https://www.wbd.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.